PGY - OTIC KZIA and PGY among pre market losers
- Otonomy ( OTIC ) -68% reports results from Phase 2 clinical trial of OTO-313 in patients with Tinnitus.
- Kazia Therapeutics ( KZIA ) -47% .
- Senti Biosciences ( SNTI ) -18% .
- FaZe Holdings ( FAZE ) -17% .
- Beam Therapeutics ( BEAM ) -11% as FDA issues clinical hold on blood cancer candidate.
- Pagaya Technologies ( PGY ) -7% .
- ON Semiconductor ( ON ) -6% on Q2 results.
- Comera Life Sciences ( CMRA ) -6% .
For further details see:
OTIC, KZIA and PGY among pre market losers